鼻内接种疫苗诱导针对SARS-CoV-2变异株的交叉保护性分泌型IgA抗体并降低肺部嗜酸性免疫病理风险
本研究在小鼠模型中评估以CpG寡核苷酸ODN2006为佐剂的重组三聚体刺突蛋白鼻内疫苗。该疫苗诱导全身性IgG及鼻黏膜分泌型IgA,分泌型IgA对Alpha、Beta和Gamma变异株的保护力高于血清IgG;与铝佐剂皮下接种相比,鼻内接种诱导Th1型应答并减少病毒攻击后的肺部嗜酸性免疫病理。
要点
- 鼻内接种ODN2006佐剂疫苗诱导鼻黏膜分泌型IgA和全身性IgG。
- 分泌型IgA对SARS-CoV-2 Alpha、Beta和Gamma变异株的保护力高于血清IgG。
- 与铝佐剂皮下接种相比,鼻内接种诱导Th1型应答并减少肺部嗜酸性免疫病理。
核心结论
- 以ODN2006为佐剂的鼻内疫苗可能是预防抗原性不同变异株感染并降低疫苗相关增强性呼吸道疾病风险的候选疫苗。
研究设计与样本
- 在小鼠模型中研究以CpG寡核苷酸ODN2006为佐剂的重组三聚体刺突蛋白鼻内接种所诱导的抗病毒保护效果。
主要发现
- 鼻内疫苗联合ODN2006成功诱导全身性刺突特异性IgG抗体以及鼻黏膜分泌型IgA抗体。
- 分泌型IgA抗体对SARS-CoV-2 Alpha、Beta和Gamma变异株的保护能力高于血清IgG抗体。
- 与以铝为典型Th2佐剂的皮下接种相比,该配方鼻内接种在引流颈部淋巴结中诱导大量IFN-γ分泌细胞,并诱导较低的刺突特异性IgG1/IgG2a比值。
- 上述特征与Th1适应性免疫应答的诱导一致。
- 病毒攻击后,鼻内接种ODN2006的小鼠肺部嗜酸性免疫病理少于铝佐剂皮下接种的小鼠。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To control the coronavirus disease 2019 (COVID-19) pandemic, there is a need to develop vaccines to prevent infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. One candidate is a nasal vaccine capable of inducing secretory IgA antibodies in the mucosa of the upper respiratory tract, the initial site of infection. However, regarding the development of COVID-19 vaccines, there is concern about the potential risk of inducing lung eosinophilic immunopathology as a vaccine-associated enhanced respiratory disease as a result of the T helper 2 (Th2)-dominant adaptive immune response. In this study, we investigated the protective effect against virus infection induced by intranasal vaccination of recombinant trimeric spike protein derived from SARS-CoV-2 adjuvanted with CpG oligonucleotides, ODN2006, in mouse model. The intranasal vaccine combined with ODN2006 successfully induced not only systemic spike-specific IgG antibodies, but also secretory IgA antibodies in the nasal mucosa. Secretory IgA antibodies showed high protective ability against SARS-CoV-2 variants (Alpha, Beta and Gamma variants) compared to IgG antibodies in the serum. The nasal vaccine of this formulation induced a high number of IFN-γ-secreting cells in the draining cervical lymph nodes and a lower spike-specific IgG1/IgG2a ratio compared to that of subcutaneous vaccination with alum as a typical Th2 adjuvant. These features are consistent with the induction of the Th1 adaptive immune response. In addition, mice intranasally vaccinated with ODN2006 showed less lung eosinophilic immunopathology after viral challenge than mice subcutaneously vaccinated with alum adjuvant. Our findings indicate that intranasal vaccine adjuvanted with ODN2006 could be a candidate that can prevent the infection of antigenically different variant viruses, reducing the risk of vaccine-associated enhanced respiratory disease.
引用
- Hemmi T, Ainai A, Hashiguchi T, et al. Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology. Vaccine. 2022. PMID: 36064667. doi:10.1016/j.vaccine.2022.08.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。